CancerLinQ Engages Leading Technology Companies Tempus and Precision HealthAI to Accelerate Data-Driven Insights to Oncologists and the Cancer Care Community

Dec 21, 2017

CancerLinQ LLC and the data services companies Tempus and Precision HealthAI have entered into an agreement that will accelerate development and delivery of high-quality, de-identified clinical databases for use by CancerLinQ®, its oncologist subscribers, partners, and the broader cancer community. The agreement will also enable CancerLinQ to more quickly build and expand on its core data sharing and quality improvement platform for oncology practices.

ASCO CEO Clifford A. Hudis, MD, FACP, FASCO, discusses this strategic collaboration with The Cancer Letter, which you can read here

Back to Top